CMS Obtained Exclusive License of a Regenerative Medical Aesthetic Product On May 30, the subsidiary of China Medical System Holdings Limited (“CMS” or the “Group”) – a dermatology and medical aesthetic company “CMS Aesthetics” entered into an exclusive license agreement with Jiangsu Xihong Biopharma Co., Ltd.(“Xihong Biopharma”) for Poly-L-lactic Acid Microparticle Filler Injection (the “Product”). In accordance with the license agreement, CMS Aesthetics obtained an exclusive license to promote, market and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan. The exclusive license period shall begin from the date of the approval of the registration certificate of class III medical device of the Product in Mainland China and shall last until the tenth anniversary of the aforementioned date of approval. Upon the expiration of the aforementioned term, the license period may automatically be extended for another period of ten years thereafter if it complies with […]
Learn More
On May 30, China Medical System Holdings Limited (“CMS” or the “Group”) announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMETRI is a humanized lgG1/κ monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMETRI has patents on composition and formulation in China. The results of the extended study of its Phase III clinical trial in China demonstrated that the primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level […]
Learn More
On May 15, Hang Seng Indexes Company newly launched the Hang Seng Innovative Drug Index, in which CMS has been included. The purpose of setting the Hang Seng Innovative Drug Index is to reflect the performance of companies engaged in the research， development and manufacture of innovative drugs，and are listed in Hong Kong. The index uses the Constituents of the Hang Seng Composite Index as the universe. Each eligible security will be assigned with a Relevance Score according to its business exposure to the innovative drug industry. The top 40 securities with the highest Relevance Score Rank will be selected as constituents. Being included in the index reflects the capital market’s recognition of the Group’s comprehensive strength of innovative R&D. After 5 years of efficient innovative products layout, CMS has collaborated with around 20 global biotech companies and biopharma and established a differentiated innovative pipeline with 30 innovative products, mainly […]
Learn More